# Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

> **NCT05078879** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 4 (actual)

## Conditions studied

- Crohn's Disease
- Glycogen Metabolism
- Inflammatory Bowel Disease (IBD)

## Interventions

- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT05078879
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2025-05-02
- **Final completion:** 2025-05-21
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078879, "Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05078879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*